IL159890A0 - Dolastatin 10 derivatives - Google Patents

Dolastatin 10 derivatives

Info

Publication number
IL159890A0
IL159890A0 IL15989002A IL15989002A IL159890A0 IL 159890 A0 IL159890 A0 IL 159890A0 IL 15989002 A IL15989002 A IL 15989002A IL 15989002 A IL15989002 A IL 15989002A IL 159890 A0 IL159890 A0 IL 159890A0
Authority
IL
Israel
Prior art keywords
dolastatin
derivatives
Prior art date
Application number
IL15989002A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL159890A0 publication Critical patent/IL159890A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15989002A 2001-07-19 2002-07-17 Dolastatin 10 derivatives IL159890A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01117410 2001-07-19
PCT/EP2002/007931 WO2003008378A1 (en) 2001-07-19 2002-07-17 Dolastatin 10 derivatives

Publications (1)

Publication Number Publication Date
IL159890A0 true IL159890A0 (en) 2004-06-20

Family

ID=8178073

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15989002A IL159890A0 (en) 2001-07-19 2002-07-17 Dolastatin 10 derivatives

Country Status (30)

Country Link
US (1) US6737409B2 (xx)
EP (1) EP1412328B1 (xx)
JP (1) JP2004534859A (xx)
KR (2) KR100611540B1 (xx)
CN (1) CN1553897A (xx)
AR (1) AR036175A1 (xx)
AT (1) ATE341537T1 (xx)
BR (1) BR0211289A (xx)
CA (1) CA2453987A1 (xx)
CO (1) CO5550462A2 (xx)
DE (1) DE60215179T2 (xx)
DK (1) DK1412328T3 (xx)
ES (1) ES2272763T3 (xx)
GT (1) GT200200154A (xx)
HR (1) HRP20040043A2 (xx)
HU (1) HUP0401253A2 (xx)
IL (1) IL159890A0 (xx)
MX (1) MXPA04000577A (xx)
MY (1) MY127718A (xx)
NO (1) NO20040198L (xx)
NZ (1) NZ530655A (xx)
PA (1) PA8551001A1 (xx)
PE (1) PE20030258A1 (xx)
PL (1) PL367682A1 (xx)
PT (1) PT1412328E (xx)
RU (1) RU2296750C2 (xx)
SI (1) SI1412328T1 (xx)
UY (1) UY27388A1 (xx)
WO (1) WO2003008378A1 (xx)
ZA (1) ZA200400334B (xx)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
NZ555951A (en) * 2002-03-22 2009-01-31 Eisai Co Ltd Hemiasterlin derivatives and uses thereof
US7064211B2 (en) 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
ES2556641T3 (es) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
WO2005118525A1 (en) * 2004-06-02 2005-12-15 F.Hoffmann-La Roche Ag Synthesis of amino-alkoxy-heptanoic alkyl ester
JP2008519863A (ja) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド Ｎ末端にアミノ安息香酸単位を有するオーリスタチン
RU2007126358A (ru) * 2004-12-13 2009-01-20 Ф.Хоффманн-Ля Рош Аг (Ch) Новая фармацевтическая композиция, содержащая по меньшей мере одно производное доластатина 10
EP1828117A1 (en) * 2004-12-13 2007-09-05 F. Hoffmann-Roche AG Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives
US20060189893A1 (en) * 2005-01-06 2006-08-24 Diamics, Inc. Systems and methods for detecting abnormal cells
US20060161076A1 (en) * 2005-01-06 2006-07-20 Diamics, Inc. Systems and methods for collection of cell clusters
AU2006205909A1 (en) * 2005-01-13 2006-07-20 F. Hoffmann-La Roche Ag New one-step synthesis of useful disubstituted amines
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
ES2708763T3 (es) 2005-07-07 2019-04-11 Seattle Genetics Inc Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
NZ572836A (en) 2006-05-16 2011-12-22 Pharmascience Inc Iap bir domain binding compounds
US20080003652A1 (en) * 2006-06-28 2008-01-03 Hans Iding Novel enzymatic process for the manufacture of Boc-Dap-Oh priority to related application(s)
PE20090481A1 (es) 2007-07-16 2009-05-18 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
RS52305B (en) 2007-07-16 2012-12-31 Genentech Inc. ANTI-CD79B ANTIBODIES AND IMMUNOCONCULATES AND METHODS OF USE
ES2587392T3 (es) 2008-01-31 2016-10-24 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
US8609105B2 (en) 2008-03-18 2013-12-17 Seattle Genetics, Inc. Auristatin drug linker conjugates
CN102933231B (zh) 2010-02-10 2015-07-29 伊缪诺金公司 Cd20抗体及其用途
SG182724A1 (en) 2010-02-12 2012-08-30 Pharmascience Inc Iap bir domain binding compounds
EP2579887B1 (de) 2010-06-10 2014-11-12 Seattle Genetics, Inc. Neue auristatin-derivate und ihre verwendung
US8987209B2 (en) 2010-09-29 2015-03-24 Seattle Genetics, Inc. N-carboxyalkyl-auristatin and the use thereof
US9029406B2 (en) 2011-03-16 2015-05-12 Seattle Genetics, Inc N-carboxyalkylauristatins and use thereof
KR102356286B1 (ko) * 2011-05-27 2022-02-08 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
DK3170821T3 (da) * 2011-05-27 2021-10-11 Ambrx Inc Sammensætninger som indeholder, fremgangsmåder som involverer, og anvendelser af ikke-naturlige aminosyrebundne dolastatinderivater
US9278996B2 (en) 2012-09-20 2016-03-08 Celltrion, Inc. Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same
EP3086815B1 (en) 2013-12-27 2022-02-09 Zymeworks Inc. Sulfonamide-containing linkage systems for drug conjugates
EP3262071B8 (en) 2014-09-23 2022-05-18 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
CN105949277B (zh) * 2015-05-05 2019-03-01 成都永泰诺科技有限公司 一种抗肿瘤化合物及其用途
WO2017170637A1 (ja) * 2016-03-29 2017-10-05 東レ株式会社 ペプチド誘導体及びその用途
CN109021065B (zh) * 2017-06-08 2021-10-01 复旦大学 一种制备海兔毒素Dolastatin10的方法
JPWO2023033129A1 (xx) 2021-09-03 2023-03-09

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides

Also Published As

Publication number Publication date
DE60215179D1 (de) 2006-11-16
WO2003008378A1 (en) 2003-01-30
MY127718A (en) 2006-12-29
AR036175A1 (es) 2004-08-18
KR20060057652A (ko) 2006-05-26
NZ530655A (en) 2006-08-31
DK1412328T3 (da) 2007-02-12
ES2272763T3 (es) 2007-05-01
JP2004534859A (ja) 2004-11-18
KR20040023661A (ko) 2004-03-18
EP1412328A1 (en) 2004-04-28
ZA200400334B (en) 2005-06-29
PE20030258A1 (es) 2003-03-19
NO20040198L (no) 2004-02-19
PT1412328E (pt) 2007-01-31
PA8551001A1 (es) 2003-09-17
DE60215179T2 (de) 2007-10-18
CO5550462A2 (es) 2005-08-31
HRP20040043A2 (en) 2004-08-31
EP1412328B1 (en) 2006-10-04
GT200200154A (es) 2003-05-16
UY27388A1 (es) 2003-01-31
SI1412328T1 (sl) 2007-02-28
CA2453987A1 (en) 2003-01-30
ATE341537T1 (de) 2006-10-15
US6737409B2 (en) 2004-05-18
RU2296750C2 (ru) 2007-04-10
BR0211289A (pt) 2004-08-03
CN1553897A (zh) 2004-12-08
MXPA04000577A (es) 2004-04-20
KR100611540B1 (ko) 2006-08-10
HUP0401253A2 (hu) 2004-12-28
PL367682A1 (en) 2005-03-07
US20030055002A1 (en) 2003-03-20
RU2004105145A (ru) 2005-07-10

Similar Documents

Publication Publication Date Title
IL159890A0 (en) Dolastatin 10 derivatives
TW595857U (en) 091219345
IL160701A0 (en) 3-substituted-4-pyrimidone derivatives
HK1068607A1 (en) Phenylalkyloxy-phenyl derivatives
HUP0303186A3 (en) 4-aminobenzopyran derivatives
HUP0401949A3 (en) 4-imidazolin-2-one derivatives
HUP0500026A3 (en) N-heteroarylnicotinamide derivatives
GB0113342D0 (en) Novel Heterocycles 1
EP1392317A4 (en) SUBSTITUTED 1-BENZAZEPINE AND DERIVATIVES THEREOF
GB0113344D0 (en) Novel heterocycles 3
EP1364954A4 (en) Dicarba closo DODECARBORANDERIVATE
EP1364653A4 (en) CASOASE-3 INHIBITORS
GB0113343D0 (en) Novel Heterocycles 2
GB0104243D0 (en) Floodstoppers 2
AU2002361351A1 (en) 24 volt-battery device
GB0007203D0 (en) Supertrowel 2000
GB0116704D0 (en) Unistore 800
TW539396U (en) 090220607
GB0118315D0 (en) Jackit 31
GB0118917D0 (en) Biopower 3
TW539394U (en) 090212946
GB0118178D0 (en) July 24
GB0118177D0 (en) July 25
GB0125582D0 (en) Fotwear designs 4
GB0129650D0 (en) 'DVT-nomore'